Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. New Zealand
  4. New Zealand Stock Exchange
  5. EBOS Group Limited
  6. News
  7. Summary
    EBO   NZEBOE0001S6

EBOS GROUP LIMITED

(EBO)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

EBOS : 2021 Full Year Results Investor Presentation

08/17/2021 | 06:24pm EDT

INVESTOR PRESENTATION

Annual Financial Results

Full year ended 30 June 2021

18 August 2021

DISCLAIMER

The information in this presentation was prepared by EBOS Group Limited ("EBOS" or the "Group") with due care and attention. However, the information is supplied in summary form and is therefore not necessarily complete, and, to the extent permitted by law, no representation is made as to the accuracy, completeness or reliability of the information. In addition, neither EBOS nor any of its subsidiaries, directors, employees, shareholders nor any other person shall have liability whatsoever to any person for any loss (including, without limitation, arising from any fault or negligence) arising from this presentation or any information supplied in connection with it.

This presentation may contain forward-looking statements and projections. These reflect EBOS' current expectations, based on what it thinks are reasonable assumptions. To the extent permitted by law, EBOS gives no warranty or representation as to its future financial performance or any future matter. Except as required by law or NZX or ASX listing rules, EBOS is not obliged to update this presentation after its release, even if things change materially. This presentation does not constitute financial advice. Further, this presentation is not and should not be construed as an offer to sell or a solicitation of an offer to buy EBOS securities and may not be relied upon in connection with any purchase of EBOS securities.

This presentation contains a number of non-GAAP financial measures, including Gross Profit, Gross Operating Revenue, EBIT, EBITA, EBITDA, NPAT, Underlying EBITDA, Underlying EBIT, Underlying NPAT, Underlying Earnings per Share, Free Cash Flow, Interest cover, Net Debt, Underlying Net Debt and Return on Capital Employed. Because they are not defined by GAAP or IFRS, EBOS' calculation of these measures may differ from similarly titled measures presented by other companies and they should not be considered in isolation from, or construed as an alternative to, other financial measures determined in accordance with GAAP. Although EBOS believes they provide useful information in measuring the financial performance and condition of EBOS' business, readers are cautioned not to place undue reliance on these non-GAAP financial measures.

The information contained in this presentation should be considered in conjunction with the consolidated financial statements for the year year ended 30 June 2021.

All currency amounts are in Australian dollars unless stated otherwise.

All amounts are presented inclusive of IFRS16 Leases, except for periods FY19 and prior, unless stated otherwise.

Underlying results exclude the impact of one-off items. Refer to page 29 for the reconciliation of Statutory to Underlying earnings.

2

GROUP FINANCIAL RESULTS

3

FY21 SUMMARY RESULTS

EBOS' strong performance has continued with another record result

$m

Underlying

Var

Statutory

Var

Revenue

9,203

5.0%

9,203

5.0%

EBITDA

367.1

9.2%

363.3

8.9%

EBIT

294.5

11.9%

290.7

11.6%

NPAT

188.2

15.5%

185.3

14.0%

EPS (cents)

114.9

14.0%

113.2

12.5%

DPS (NZ cents)

88.5

14.2%

ROCE (%)

18.0%

0.9%

Net debt : EBITDA (x)

0.85x

0.26x

Double-digit

Record ROCE

Investing for growth

Strong balance sheet

Increased dividends

earnings growth

to shareholders

4

KEY HIGHLIGHTS

Strong organic growth in Healthcare and Animal Care and investing for future growth

Healthcare

EBIT up 11.4%1

  • Healthcare's strong performance was driven by our Community Pharmacy, TerryWhite Chemmart ("TWC"), Institutional Healthcare and Contract Logistics businesses. Key highlights included:
  1. Community Pharmacy wholesale volume growth;
  1. TWC network sales growth of 5.3% and 36 net new trading stores added to the network;
  1. Institutional Healthcare growth driven by specialty medicines and medical consumables demand and medical devices growth;
  1. Acquisition of Pioneer Medical, a New Zealand based medical devices distribution business; and
  1. Cost savings compared to last year primarily from improvements in productivity in wholesale operations.

Animal Care

EBIT up 26.4%

  • Animal Care's Vitapet, Black Hawk and Lyppard businesses maintained double-digit sales growth. Key highlights included:
  1. Our key pet brands, Black Hawk and Vitapet strengthened their market positions and capitalised on strong pet care market conditions;
  1. Lyppard continued its strong performance in the vet, retail and online channels, and benefitted from the acquisition of CH2's vet distribution business announced in H1 FY21; and

o Construction of a new state of the art pet food manufacturing facility.

Group

NPAT up 15.5%1

  • Excellent operating cash flow of $298.3m.
  • ROCE of 18.0%, which is a record for the Group.
  • Further strengthened the balance sheet, with Net Debt : EBITDA reducing to 0.85x. EBOS has no debt maturities until H2 FY23.

5

Note 1:

Growth

rates are

calculated

based o

n Und

erlying

EBIT and

Underlying NPAT

(as

applicable).

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

EBOS Group Limited published this content on 18 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 August 2021 22:23:07 UTC.


© Publicnow 2021
All news about EBOS GROUP LIMITED
09/22EBOS Group Limited Announces Supplementary Dividend for the Six Months Ended June 30, 2..
CI
09/22EBOS Group Limited Announces Ordinary Dividend for the Six Months Ended June 30, 2021, ..
CI
09/21EBOS : Names Animal Care Division CEO; Shares Up 3%
MT
09/21EBOS Group Limited Appoints Julie Dillon as CEO, Animal Care, Effective 1 November 2021
CI
09/01EBOS : Acquires Sentry Medical
MT
09/01EBOS Group Limited acquired Sentry Medical.
CI
08/18EBOS Group Limited acquired Pioneer Medical Limited for AUD 40 million.
CI
08/17Australia shares rise as upbeat earnings counter BHP slide
RE
08/17EBOS Group Seeks Acquisitions
CI
08/17EBOS : 2021 Full Year Results Investor Presentation
PU
More news
Financials
Sales 2022 10 113 M 7 258 M 7 258 M
Net income 2022 219 M 157 M 157 M
Net Debt 2022 355 M 255 M 255 M
P/E ratio 2022 26,2x
Yield 2022 2,64%
Capitalization 5 796 M 4 174 M 4 159 M
EV / Sales 2022 0,61x
EV / Sales 2023 0,58x
Nbr of Employees 3 105
Free-Float 79,9%
Chart EBOS GROUP LIMITED
Duration : Period :
EBOS Group Limited Technical Analysis Chart | EBO | NZEBOE0001S6 | MarketScreener
Technical analysis trends EBOS GROUP LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 35,30 NZD
Average target price 33,32 NZD
Spread / Average Target -5,62%
EPS Revisions
Managers and Directors
John Cullity Chief Executive Officer
Leonard Hansen Chief Financial Officer
Elizabeth Mary Coutts Chairman
Andrea Bell Chief Information Officer
Sarah Christine Ottrey Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
EBOS GROUP LIMITED23.00%4 174
WALGREENS BOOTS ALLIANCE, INC.21.34%41 887
JD HEALTH INTERNATIONAL INC.-47.17%32 479
MCKESSON CORPORATION18.50%31 877
CARDINAL HEALTH, INC.-9.20%13 978
HUADONG MEDICINE CO., LTD29.29%9 399